Selecting CAR T-Cell Therapies for Mantle Cell Lymphoma: Jae Park, MD

Video

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Jae Park, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, about factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Differences in these agents can be observed with respect to their individual safety profiles, according to Park. For example, lisocabtagene maraleucel (liso-cel; Breyanzi) is associated with fewer reports of cytokine release syndrome (CRS) and neurotoxicity; however, it is still important to review the manufacturing details, as this agent has now been commercialized, Park explains. Additionally, although axicabtagene ciloleucel (axi-cel; Yescarta) has a faster turnaround time with regard to manufacturing, resulting in more rapid availability, higher rates of CRS and neurotoxicity have also been reported with the product, Park notes.

The key factors to consider when making treatment decisions often include turnaround time, manufacturing success, and reliability of delivery, as well as the frequency and intensity of the monitoring required for patients, Park explains. Despite the complicated decision-making process, having a range of options available for patients is beneficial, Park concludes.

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Related Content
© 2024 MJH Life Sciences

All rights reserved.